Methylisoeugenol

Methylisoeugenol

SCHEMBL1532669

C/C=C/c1ccc(OC)c(OC)c1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.69
MAPT P10636 3/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
LMNA P02545 2/20 0.66
HTT P42858 2/20 0.66
NPSR1 Q6W5P4 1/20 0.66
CYP1A1 P04798 5/20 0.66
CYP1B1 Q16678 4/20 0.66
CYP1A2 P05177 2/20 0.66
TUBB4A P04350 1/20 0.66
TUBB P07437 1/20 0.66
TUBA3C P0DPH7 1/20 0.66
TUBA1B P68363 1/20 0.66
TUBA4A P68366 1/20 0.66
TUBB4B P68371 1/20 0.66
TUBB3 Q13509 1/20 0.66
TUBB2A Q13885 1/20 0.66
TUBB8 Q3ZCM7 1/20 0.66
TUBA3E Q6PEY2 1/20 0.66
TUBA1A Q71U36 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylisoeugenol SCHEMBL29518298 1.00 TYR (0.69) TYRMAPTSMN1; SMN2LMNAHTT
Methylisoeugenol SCHEMBL29364555 1.00 TYR (0.69) TYRMAPTSMN1; SMN2LMNAHTT
Methylisoeugenol SCHEMBL30203196 1.00 TYR (0.69) TYRMAPTSMN1; SMN2LMNAHTT
Methylisoeugenol SCHEMBL1760676 1.00 TYR (0.69) TYRMAPTSMN1; SMN2LMNAHTT
Methylisoeugenol SCHEMBL112937 1.00 TYR (0.69) TYRMAPTSMN1; SMN2LMNAHTT
Methylisoeugenol SCHEMBL28544349 0.98 TYR (0.67) TYRMAPTSMN1; SMN2LMNAHTT
Methylisoeugenol SCHEMBL28577260 0.98 TYR (0.67) TYRMAPTSMN1; SMN2LMNAHTT
SCHEMBL27943686 0.92 TYR (0.65) TYRMAPTSMN1; SMN2LMNAHTT
Methylisoeugenol SCHEMBL432122 0.89 TYR (0.90) TYRMAPTLMNAHTTNPSR1
Methylisoeugenol SCHEMBL29136251 0.89 POLB (0.70) TYRMAPTSMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559703-B2 Fragrance composition GIVAUDAN SA (CH) 2026-02-24 US claimed
EP-4581114-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Novozymes A/S (DK) 2025-07-09 EP claimed
US-20250134790-A1 ANTIMICROBIAL COMPOSITIONS FIRMENICH SA (CH) 2025-05-01 US claimed
CN-119698458-A Improvements in or relating to organic compounds improvements relating to organic compounds 诺维信公司 2025-03-25 CN claimed
CN-113784759-B Fragrance composition 弗门尼舍有限公司 2024-07-05 CN claimed
CN-118275560-A Content determination and volatile oil fingerprint construction method for beta-asarone in grassleaf sweelflag rhizome 天津中医药大学 2024-07-02 CN claimed
EP-4387583-A1 ANTIMICROBIAL COMPOSITIONS Firmenich SA (CH) 2024-06-26 EP claimed
CN-118105365-A Use of a compound in the manufacture of a medicament for preventing or treating idiopathic vomiting in a companion animal 马斯公司 2024-05-31 CN claimed
US-20240173230-A1 FRAGRANCE COMPOSITION GIVAUDAN SA (CH) 2024-05-30 US claimed
CN-118059089-A Aromatic and anti-influenza prescription volatile oil preparation for preventing influenza and preparation method and application thereof 中国中医科学院中医临床基础医学研究所 2024-05-24 CN claimed
EP-2836579-B1 MALODOR REDUCTION COMPOSITIONS PROCTER & GAMBLE (US) 2018-07-25 EP claimed
CN-108143727-A The new application of allyl benzene derivatives 天津中医药大学 2018-06-12 CN claimed
WO-2018050721-A1 FRAGRANCE COMPOSITIONS GIVAUDAN SA (CH) 2018-03-22 WO claimed
CN-107793231-A A kind of Chinese cassia tree fertilizer and preparation method 广西垚宇贸易有限公司 2018-03-13 CN claimed
EP-2986136-A1 COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING The Iams Company (US) 2016-02-24 EP claimed
CN-105188400-A Compositions and methods for preventing, reducing, alleviating, or treating idiopathic vomiting IAMS COMPANY 2015-12-23 CN claimed
WO-2014143539-A1 COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING THE IAMS COMPANY (US) 2014-09-18 WO claimed
US-20140271949-A1 Composition and Method for Preventing, Reducing, Alleviating or Treating Idiopathic Vomiting THE IAMS COMPANY (US) 2014-09-18 US claimed
EP-1993580-A1 COMBINATION THERAPY FOR TREATMENT OF PATIENTS WITH NEUROLOGICAL DISORDERS AND CEREBRAL INFARCTION Moleac Pte Ltd. (SG) 2008-11-26 EP claimed
WO-2007106049-A1 COMBINATION THERAPY FOR TREATMENT OF PATIENTS WITH NEUROLOGICAL DISORDERS AND CEREBRAL INFARCTION MOLEAC PTE LTD (SG) 2007-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559703-B2 Fragrance composition DHCR24, OPRD1, OR10J3 TYR 1284/4885MAPT 4309/4885SMN1; SMN2 3767/4885
US-20240173230-A1 FRAGRANCE COMPOSITION FABP2, FABP5, FAAH2 TYR 246/4885MAPT 2375/4885SMN1; SMN2 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.